Polaris Pharmaceuticals

Polaris Pharmaceuticals, Inc., headquartered in San Diego, is leading the clinical development of the Polaris Group's main candidate drug, Pegargiminase. Established in 2006, the company also conducts early-stage drug discovery, translational research, and preclinical studies for various cancer indications, and is carrying out global clinical trials for Pegargiminase.